Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Post by Ticklel1ston Jun 19, 2019 5:33pm

143 Views

Post# 29841734

Impossible to evaluate the deal with no numbers.

Again, I think Sirona is lucky to not lose market cap after this NR. The market wants financial details, like Sirona provided with Wangbang NR so long ago.

Roof of share price is in the finacial details Howie... I'm not surprised with the same old same old from Howie.

Bullboard Posts

Gold Flora's Gramlin holds court in California cannabis market